We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Performance Evaluated for Point-of-Care HbA1c Analyzer

By LabMedica International staff writers
Posted on 07 Jul 2015
Print article
The SD A1cCare point-of-care analyzer
The SD A1cCare point-of-care analyzer (Photo courtesy of SD BIOSENSOR)
Glycated hemoglobin (HbA1c) levels, which reflect the average plasma glucose concentration over the preceding three months, play a pivotal role in the diagnosis, assessment, and monitoring of diabetes.

The immediate feedback of HbA1c levels is highly effective for controlling plasma glucose levels and point-of-care (POC) instruments, characterized as fast, portable, and easy-to-use, have been shown to be suitable for providing rapid feedback of HbA1c levels.

Medical laboratory scientists at the Seoul National University College of Medicine (Republic of Korea) assessed the analytical performance of a newly developed POC HbA1c analyzer. To investigate the accuracy of the analyzer, they measured the deviation from the International Federation of Clinical Chemistry (IFCC) reference targets using two sets of 12 duplicate fresh venous whole blood specimens with a range of 33.3 mmol/mol to 91.3 mmol/mol in International System of Units (SI) units, or 5.2% to 10.5% in National Glycohemoglobin Standardization Program (NSGP) units.

The SD A1cCare analyzer (SD Biosensor, Inc.; Suwon, Korea), which utilizes an immunochromatography assay, was used to measures total hemoglobin and HbA1c levels via its optical system and calculates the percentage HbA1c. The SD A1cCare Test kit uses an anti-HbA1c antibody that is specific for the first few amino acid residues of the glycated N-terminus of the β-chain of hemoglobin A0. The scientists tested 150 residual specimens using both the SD A1cCare and the Variant II Turbo (Bio-Rad Laboratories, Inc.; Hercules, CA, USA) in 14 days.

The SD A1cCare POC HbA1c analyzer showed excellent precision, linearity and correlation with Variant II Turbo high-performance liquid chromatography (HPLC) and it showed excellent accuracy with IFCC targets. Deviations from IFCC targets at 30, 60, and 90 mmol/mol IFCC levels were − 1.95, − 1.85, and − 1.74 mmol/mol, respectively. The coefficients of variation based on EP9-A2 protocol were 2.6% in SI units and 1.8% in NGSP units.

The authors concluded that the SD A1cCare analyzer showed excellent precision, linearity, correlation with the Variant II Turbo analyzer, and accuracy with IFCC targets and therefore, it may be suitable for HbA1c assays in the POC setting and in small laboratories. The study was published in the June, 2015 issue of the journal Clinical Biochemistry.

Related Links:

Seoul National University College of Medicine 
SD Biosensor Inc.
Bio-Rad Laboratories 


New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.